43 results on '"Yeung Yik Andy"'
Search Results
2. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
3. Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire.
4. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity
5. CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus
6. CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus
7. 1048 AB821 is a CD8+T cell selective IL-21 with enhanced bioavailability that reduces CD8+T cell exhaustion to induce potent antitumor activity
8. 1006 High doses of MHC-II neoantigens in peptide cancer vaccines induce tumor-specific inhibitory cytolytic CD4+T cells
9. Figure S5 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
10. Data from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
11. Tables and Methods from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
12. Supplementary Tables 1 - 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
13. Supplementary Figure 3 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
14. Supplementary Figure 5 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
15. Supplementary Figure 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
16. Supplementary Figure 2 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
17. Supplementary Figure 1 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
18. Supplementary Figure Legends 1-6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
19. Supplementary Figure 6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
20. Data from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
21. Abstract 561: CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy
22. Abstract 3518: AB248 is a CD8+ T cell selective IL-2 designed for superior safety and anti-tumor efficacy
23. 578 CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
24. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
25. Introduction: Antibody Structure and Function
26. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics
27. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity
28. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
29. This title is unavailable for guests, please login to see more information.
30. Integrated Mimicry of B Cell Antibody Mutagenesis Using Yeast Homologous Recombination
31. Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia
32. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
33. A Novel Full Length Anti-FLT3 CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia
34. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
35. Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
36. Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration
37. Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms
38. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity
39. High-Throughput Epitope Binning Assays on Label-Free Array-Based Biosensors Can Yield Exquisite Epitope Discrimination That Facilitates the Selection of Monoclonal Antibodies with Functional Activity
40. Antibody engineering for cancer therapy
41. A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
42. Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
43. Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.